BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BPL-003 (mebufotenin benzoate) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BPL-003 (mebufotenin benzoate)\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05660642-821@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BPL-003 (mebufotenin benzoate): Phase 2 readout est. (NCT05660642)
DESCRIPTION:BPL-003 (mebufotenin benzoate)\, phase 2\, Major Depressive Dis
 order.\nStudy: An Open-Label Study to Evaluate the Safety\, Tolerability a
 nd Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depres
 sion\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bpl-003-mebufotenin-benzoate#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05660642
URL:https://assetmemo.bio/drug/bpl-003-mebufotenin-benzoate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
